Core Insights - The Beauty Health Company reported financial results for Q4 2025, indicating structural progress in margins, profitability, and balance sheet strength [1][2] Financial Performance - Q4 2025 net sales were $82.4 million, a decrease of 1.3% from Q4 2024, attributed to lower delivery systems net sales [6][11] - Gross margin improved to 64.4% in Q4 2025 from 62.7% in Q4 2024, driven by lower inventory-related charges and a favorable shift towards consumable net sales [6][11] - Operating expenses decreased to $52.9 million in Q4 2025 from $59.5 million in Q4 2024, primarily due to lower personnel and marketing-related expenses [7][11] - The net loss for Q4 2025 was $(8.1) million, an improvement from $(10.3) million in Q4 2024 [11][33] - Adjusted EBITDA for Q4 2025 was $15.0 million, up from $9.0 million in Q4 2024, reflecting lower operational spend and higher gross margin [11][33] Annual Financial Highlights - Total net sales for 2025 were $300.8 million, a decrease of 10.0% compared to 2024, due to lower delivery systems net sales [11][12] - Gross margin for 2025 was 65.3%, up from 54.5% in 2024, with adjusted gross margin at 68.2% compared to 62.0% in 2024 [11][12] - Operating expenses for 2025 were $217.2 million, down from $250.1 million in 2024, with adjusted operating expenses at $160.0 million compared to $194.9 million in 2024 [11][12] - The net loss for 2025 was $(9.5) million, significantly improved from $(29.1) million in 2024 [11][12] Operational Metrics - The company sold 1,032 delivery systems in Q4 2025, down from 1,087 in Q4 2024, with a total of 3,726 systems sold in 2025 compared to 4,907 in 2024 [4][11] - The active install base remained stable at 36,026 systems as of December 31, 2025, compared to 34,735 in 2024 [4][11] Cash Flow and Balance Sheet - Cash, cash equivalents, and restricted cash were approximately $233 million as of December 31, 2025, down from $370 million in 2024, primarily due to the repurchase of convertible senior notes [11][12] - The company repurchased $21.3 million principal amount of the 2026 Notes in February 2026 at a weighted-average price of 94.875% [11][12] 2026 Financial Guidance - For Q1 2026, the company expects net sales between $63 million and $68 million and adjusted EBITDA between $3.5 million and $5.5 million [10] - For the fiscal year 2026, net sales are projected to be between $285 million and $305 million, with adjusted EBITDA expected to be between $35 million and $45 million [10]